Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib vs platinum–pemetrexed chemotherapy in treatment‑naïve ALK‑positive advanced non‑squamous NSCLC
jRCT2080222158Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ceritinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Started Jul 2013; status: completed.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222158.